Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Treatment and prognosis of cutaneous squamous cell carcinoma

INTRODUCTION

Cutaneous squamous cell carcinoma (SCC) is a common cancer arising from malignant proliferation of the keratinocytes of the epidermis. Treatment of cutaneous SCC is indicated since progression of the tumor may lead to local tissue destruction or metastasis resulting in significant morbidity or death. Early treatment provides the best opportunity to cure cutaneous SCC.

In contrast to basal cell carcinoma (BCC), which rarely metastasizes, around 2 to 5 percent of cutaneous SCCs metastasize to regional lymph nodes or more distant sites [1-3]. The approach to treatment is dependent upon the presence or absence of tumor features and patient characteristics that portend an increased risk for aggressive tumor behavior. Cutaneous SCCs that do not have high-risk features have low frequencies of recurrence and metastasis.

The treatment of cutaneous SCCs without features associated with aggressive behavior (low-risk cutaneous SCC) and the prognosis of cutaneous SCC will be reviewed here. The management of high-risk and metastatic cutaneous SCCs, the treatment of keratoacanthomas, and the risk factors, clinical features, and diagnosis of cutaneous SCC are reviewed separately. (See "Recognition and management of high-risk (aggressive) cutaneous squamous cell carcinoma" and "Systemic treatment of advanced cutaneous squamous and basal cell carcinomas" and "Keratoacanthoma: Management and prognosis" and "Epidemiology and risk factors for cutaneous squamous cell carcinoma" and "Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)" and "Evaluation for locoregional and distant metastases in cutaneous squamous cell and basal cell carcinoma".)

APPROACH TO TREATMENT

The risk of locoregional recurrence and regional or distant metastasis is the most important factor for determining the approach to the treatment for cutaneous squamous cell carcinoma (SCC). Examples of characteristics that impact the risk for recurrence and metastasis include the site, size, and histological features of a tumor, as well as patient comorbidities (table 1). “High-risk” SCCs are tumors that exhibit characteristics that are associated with an elevated risk for aggressive tumor behavior.

A consensus on the specific characteristics that define high-risk SCC has not been established and major entities such as the National Comprehensive Cancer Network (NCCN) and the American Joint Committee on Cancer (AJCC) have described dissimilar “high-risk” criteria [4,5]. We follow the NCCN criteria when categorizing tumors as high-risk or low-risk for determining the approach to treatment (table 1). The features of high-risk cutaneous SCC are reviewed in greater detail separately. (See "Recognition and management of high-risk (aggressive) cutaneous squamous cell carcinoma".)

                   

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Aug 2014. | This topic last updated: Jan 22, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Joseph MG, Zulueta WP, Kennedy PJ. Squamous cell carcinoma of the skin of the trunk and limbs: the incidence of metastases and their outcome. Aust N Z J Surg 1992; 62:697.
  2. Brantsch KD, Meisner C, Schönfisch B, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol 2008; 9:713.
  3. Brougham ND, Dennett ER, Cameron R, Tan ST. The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors. J Surg Oncol 2012; 106:811.
  4. http://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdf (Accessed on June 22, 2013).
  5. Farasat S, Yu SS, Neel VA, et al. A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: creation and rationale for inclusion of tumor (T) characteristics. J Am Acad Dermatol 2011; 64:1051.
  6. Ad Hoc Task Force, Connolly SM, Baker DR, et al. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery. J Am Acad Dermatol 2012; 67:531.
  7. Lansbury L, Bath-Hextall F, Perkins W, et al. Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies. BMJ 2013; 347:f6153.
  8. Bath-Hextall FJ, Matin RN, Wilkinson D, Leonardi-Bee J. Interventions for cutaneous Bowen's disease. Cochrane Database Syst Rev 2013; 6:CD007281.
  9. Lansbury L, Leonardi-Bee J, Perkins W, et al. Interventions for non-metastatic squamous cell carcinoma of the skin. Cochrane Database Syst Rev 2010; :CD007869.
  10. Brodland DG, Zitelli JA. Surgical margins for excision of primary cutaneous squamous cell carcinoma. J Am Acad Dermatol 1992; 27:241.
  11. Holt PJ. Cryotherapy for skin cancer: results over a 5-year period using liquid nitrogen spray cryosurgery. Br J Dermatol 1988; 119:231.
  12. Kuflik EG. Cryosurgery updated. J Am Acad Dermatol 1994; 31:925.
  13. Kuflik EG, Gage AA. The five-year cure rate achieved by cryosurgery for skin cancer. J Am Acad Dermatol 1991; 24:1002.
  14. Zacarian SA. Cryosurgery of cutaneous carcinomas. An 18-year study of 3,022 patients with 4,228 carcinomas. J Am Acad Dermatol 1983; 9:947.
  15. Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol 1992; 26:976.
  16. KNOX JM, LYLES TW, SHAPIRO EM, MARTIN RD. Curettage and electrodesiccation in the treatment of skin cancer. Arch Dermatol 1960; 82:197.
  17. Whelan CS, Deckers PJ. Electrocoagulation and curettage for carcinoma involving the skin of the face, nose, eyelids, and ears. Cancer 1973; 31:159.
  18. Honeycutt WM, Jansen GT. Treatment of squamous cell carcinoma of the skin. Arch Dermatol 1973; 108:670.
  19. Whelan CS, Deckers PJ. Electrocoagulation for skin cancer: an old oncologic tool revisited. Cancer 1981; 47:2280.
  20. Chren MM, Linos E, Torres JS, et al. Tumor recurrence 5 years after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol 2013; 133:1188.
  21. Panje WR, Ceilley RI. The influence of embryology of the mid-face on the spread of epithelial malignancies. Laryngoscope 1979; 89:1914.
  22. Lovett RD, Perez CA, Shapiro SJ, Garcia DM. External irradiation of epithelial skin cancer. Int J Radiat Oncol Biol Phys 1990; 19:235.
  23. Petsuksiri J, Frank SJ, Garden AS, et al. Outcomes after radiotherapy for squamous cell carcinoma of the eyelid. Cancer 2008; 112:111.
  24. Johnson TM, Rowe DE, Nelson BR, Swanson NA. Squamous cell carcinoma of the skin (excluding lip and oral mucosa). J Am Acad Dermatol 1992; 26:467.
  25. Petrovich Z, Kuisk H, Langholz B, et al. Treatment of carcinoma of the skin with bone and/or cartilage involvement. Am J Clin Oncol 1988; 11:110.
  26. Kraus FT, Perezmesa C. Verrucous carcinoma. Clinical and pathologic study of 105 cases involving oral cavity, larynx and genitalia. Cancer 1966; 19:26.
  27. Perez CA, Kraus FT, Evans JC, Powers WE. Anaplastic transformation in verrucous carcinoma of the oral cavity after radiation therapy. Radiology 1966; 86:108.
  28. Demian SD, Bushkin FL, Echevarria RA. Perineural invasion and anaplastic transformation of verrucous carcinoma. Cancer 1973; 32:395.
  29. Locke J, Karimpour S, Young G, et al. Radiotherapy for epithelial skin cancer. Int J Radiat Oncol Biol Phys 2001; 51:748.
  30. Petrovich Z, Parker RG, Luxton G, et al. Carcinoma of the lip and selected sites of head and neck skin. A clinical study of 896 patients. Radiother Oncol 1987; 8:11.
  31. Kwan W, Wilson D, Moravan V. Radiotherapy for locally advanced basal cell and squamous cell carcinomas of the skin. Int J Radiat Oncol Biol Phys 2004; 60:406.
  32. Sturm HM. Bowen's disease and 5-fluorouracil. J Am Acad Dermatol 1979; 1:513.
  33. Goette DK. Topical chemotherapy with 5-fluorouracil. A review. J Am Acad Dermatol 1981; 4:633.
  34. Klein E, Stoll HL Jr, Milgrom H, et al. Tumors of the skin. XII. Topical 5-Fluorouracil for epidermal neoplasms. J Surg Oncol 1971; 3:331.
  35. Mackenzie-Wood A, Kossard S, de Launey J, et al. Imiquimod 5% cream in the treatment of Bowen's disease. J Am Acad Dermatol 2001; 44:462.
  36. Salim A, Leman JA, McColl JH, et al. Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen's disease. Br J Dermatol 2003; 148:539.
  37. Morton C, Horn M, Leman J, et al. Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or Fluorouracil for treatment of squamous cell carcinoma in situ: Results of a multicenter randomized trial. Arch Dermatol 2006; 142:729.
  38. Love WE, Bernhard JD, Bordeaux JS. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol 2009; 145:1431.
  39. Bargman H, Hochman J. Topical treatment of Bowen's disease with 5-Fluorouracil. J Cutan Med Surg 2003; 7:101.
  40. Stone N, Burge S. Bowen's disease of the leg treated with weekly pulses of 5% fluorouracil cream. Br J Dermatol 1999; 140:987.
  41. Hunter GA. Follicular Bowen's disease. Br J Dermatol 1977; 97:20.
  42. Rozenman Y, Gurewich J, Gotsman MS. Myocardial ischemia induced by topical use of 5-fluorouracil. Int J Cardiol 1995; 49:282.
  43. Johnson MR, Hageboutros A, Wang K, et al. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res 1999; 5:2006.
  44. Hamouda B, Jamila Z, Najet R, et al. Topical 5-fluorouracil to treat multiple or unresectable facial squamous cell carcinomas in xeroderma pigmentosum. J Am Acad Dermatol 2001; 44:1054.
  45. Morton CA, Szeimies RM, Sidoroff A, Braathen LR. European guidelines for topical photodynamic therapy part 1: treatment delivery and current indications - actinic keratoses, Bowen's disease, basal cell carcinoma. J Eur Acad Dermatol Venereol 2013; 27:536.
  46. Truchuelo M, Fernández-Guarino M, Fleta B, et al. Effectiveness of photodynamic therapy in Bowen's disease: an observational and descriptive study in 51 lesions. J Eur Acad Dermatol Venereol 2012; 26:868.
  47. Shimizu I, Cruz A, Chang KH, Dufresne RG. Treatment of squamous cell carcinoma in situ: a review. Dermatol Surg 2011; 37:1394.
  48. Morton CA, Whitehurst C, Moseley H, et al. Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen's disease. Br J Dermatol 1996; 135:766.
  49. Varma S, Holt PJ, Anstey AV. Erythroplasia of queyrat treated by topical aminolaevulinic acid photodynamic therapy: a cautionary tale. Br J Dermatol 2000; 142:825.
  50. Beutner KR, Spruance SL, Hougham AJ, et al. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol 1998; 38:230.
  51. Urosevic M, Dummer R, Conrad C, et al. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst 2005; 97:1143.
  52. Schön M, Bong AB, Drewniok C, et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 2003; 95:1138.
  53. Hengge UR, Stark R. Topical imiquimod to treat intraepidermal carcinoma. Arch Dermatol 2001; 137:709.
  54. Patel GK, Goodwin R, Chawla M, et al. Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen's disease): a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2006; 54:1025.
  55. Rosen T, Harting M, Gibson M. Treatment of Bowen's disease with topical 5% imiquimod cream: retrospective study. Dermatol Surg 2007; 33:427.
  56. Ondo AL, Mings SM, Pestak RM, Shanler SD. Topical combination therapy for cutaneous squamous cell carcinoma in situ with 5-fluorouracil cream and imiquimod cream in patients who have failed topical monotherapy. J Am Acad Dermatol 2006; 55:1092.
  57. Goh MS. Invasive squamous cell carcinoma after treatment of carcinoma in situ with 5% imiquimod cream. Australas J Dermatol 2006; 47:186.
  58. American Cancer Society. Cancer facts and figures 2003 www.cancer.org/docroot/STT/stt_0_2003.asp?sitearea=STT&level=1 (Accessed on April 02, 2004).
  59. Weinstock MA. Epidemiologic investigation of nonmelanoma skin cancer mortality: the Rhode Island Follow-Back Study. J Invest Dermatol 1994; 102:6S.
  60. Osterlind A, Hjalgrim H, Kulinsky B, Frentz G. Skin cancer as a cause of death in Denmark. Br J Dermatol 1991; 125:580.
  61. Kwa RE, Campana K, Moy RL. Biology of cutaneous squamous cell carcinoma. J Am Acad Dermatol 1992; 26:1.
  62. Kraus DH, Carew JF, Harrison LB. Regional lymph node metastasis from cutaneous squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1998; 124:582.
  63. Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med 2001; 344:975.
  64. Karagas MR, Stukel TA, Greenberg ER, et al. Risk of subsequent basal cell carcinoma and squamous cell carcinoma of the skin among patients with prior skin cancer. Skin Cancer Prevention Study Group. JAMA 1992; 267:3305.
  65. Schinstine M, Goldman GD. Risk of synchronous and metachronous second nonmelanoma skin cancer when referred for Mohs micrographic surgery. J Am Acad Dermatol 2001; 44:497.
  66. Wassberg C, Thörn M, Yuen J, et al. Second primary cancers in patients with squamous cell carcinoma of the skin: a population-based study in Sweden. Int J Cancer 1999; 80:511.
  67. Hemminki K, Dong C. Subsequent cancers after in situ and invasive squamous cell carcinoma of the skin. Arch Dermatol 2000; 136:647.
  68. Marghoob AA, Slade J, Salopek TG, et al. Basal cell and squamous cell carcinomas are important risk factors for cutaneous malignant melanoma. Screening implications. Cancer 1995; 75:707.
  69. Frankel DH, Hanusa BH, Zitelli JA. New primary nonmelanoma skin cancer in patients with a history of squamous cell carcinoma of the skin. Implications and recommendations for follow-up. J Am Acad Dermatol 1992; 26:720.
  70. Marcil I, Stern RS. Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol 2000; 136:1524.
  71. Chen J, Ruczinski I, Jorgensen TJ, et al. Nonmelanoma skin cancer and risk for subsequent malignancy. J Natl Cancer Inst 2008; 100:1215.
  72. Karagas MR, Greenberg ER, Mott LA, et al. Occurrence of other cancers among patients with prior basal cell and squamous cell skin cancer. Cancer Epidemiol Biomarkers Prev 1998; 7:157.
  73. Levi F, Randimbison L, La Vecchia C, et al. Incidence of invasive cancers following squamous cell skin cancer. Am J Epidemiol 1997; 146:734.
  74. Adami J, Frisch M, Yuen J, et al. Evidence of an association between non-Hodgkin's lymphoma and skin cancer. BMJ 1995; 310:1491.
  75. Cantwell MM, Murray LJ, Catney D, et al. Second primary cancers in patients with skin cancer: a population-based study in Northern Ireland. Br J Cancer 2009; 100:174.
  76. Johannesdottir SA, Lash TL, Jensen AØ, et al. Mortality in cancer patients with a history of cutaneous squamous cell carcinoma--a nationwide population-based cohort study. BMC Cancer 2012; 12:126.